Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
must weigh greater than or equal to 40kg
Patients must have diagnosis of partial seizures
At least 3 observable partial seizures a month
Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.
